Method for diagnosis of alzheimer's disease

Abstract

The invention relates to a method for diagnosis of Alzheimer's disease. Specifically, the invention relates to a method for risk detection, diagnosis, prognosis and monitoring of Alzheimer's disease (AD). The method comprises the steps of: (1) measuring the level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in a sample from the subject, and (2) comparing the level of GAPDH in the sample with two or more AD reference levels of GAPDH.

Description

technical field [0001] The present invention relates to a method for Alzheimer's disease risk detection, diagnosis, prognosis and monitoring. Background technique [0002] Alzheimer's disease (AD) is the most common form of dementia. Alzheimer's disease is classified as a neurodegenerative disorder, the causes and progression of which are not well understood. Its course expression appears to be associated with plaques and tangles in the brain. The most common early symptom is short-term memory loss – trouble remembering recent events. [0003] To date, there are no standard diagnostic tests for AD, so the diagnosis still relies on the clinical information provided by the AD patient and the confirmation of the neurological examination as the diagnosis. Typically, AD is diagnosed by tests to assess a patient's behavior and thinking abilities, often followed by a brain scan when available. However, final diagnosis requires examination of brain tissue. Methods traditionally...

AI Technical Summary

Problems solved by technology

Methods traditionally used to assess AD are either not specific (degree) or very expensive, including, for example, the Mini Mental State Examination (MMSE), which is a Functional Assessment Questionnaire (FAQ) Formal psychometric test to examine levels of functional autonomy (Tombaugh, The mini-mental state examination: a comprehensive review. J. Am. Geriatr. Soc. 40, 922-935, 1992); tau and beta-amyloid in cerebrospinal fluid Invasive detection of protein (Aβ) concentration (Wang et al., Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helicalfilament tau binding protein. FASEB J.19, 869-871, 2005); neuroimaging, especially It is computed tomography (CT), which is very expensive (Haydel et al.,Indications for computedtomography in patients with minor head injury.N.Engl.J.Med.343,100-105,2000)

Images